Google-parent Alphabet has set up a new lab that will use A.I. to try to discover new drugs

- Advertisement -


  • The company will build on research by London artificial intelligence lab DeepMind, which Google acquired in 2014.
  • Demis Hassabis, CEO and co-founder of DeepMind, is the founder and CEO of Isomorphic Labs.
  • In a blog post, Hasabis described Isomorphic Labs as a commercial venture whose mission is “to redefine the entire drug discovery process from the ground up.”

- Advertisement -

Google’s parent company Alphabet has launched a new drug discovery company, Isomorphic Labs, in the UK.

- Advertisement -

The company will build on research by London artificial intelligence lab DeepMind, which Google acquired in 2014. While the firm was officially announced on Thursday, it was incorporated in February, according to a filing with the UK Companies Registry’s Companies House.

Demis Hasabis, the CEO and co-founder of DeepMind, is also the founder and CEO of Isomorphic Labs. He will continue to be the CEO of DeepMind.

- Advertisement -

one in blog postIn , Hasabis described Isomorphic Labs as a commercial venture whose mission is to “re-imagine the entire drug discovery process from the ground up.”

A spokesperson for Isomorphic Labs stressed that the company is separate from DeepMind and has its own dedicated resources. However, he did not specify how many employees it has or how much capital it has.

“Where relevant, teams from both companies can collaborate, especially in the early days as Isomorphic Labs is hiring its own team,” the spokesperson said.

Isomorphic Labs plans to use artificial intelligence software to create new drugs and drugs.

Identifying new drugs is a long, complicated trial-and-error process that involves combining many different compounds in different ways. Several companies, including London’s BenevolentAI and San Francisco’s AtomWise, believe AI can speed up the process.

Hasabis, a former child chess prodigy with degrees in computer science and cognitive neuroscience, wrote, “We believe that the foundational use of state-of-the-art computational and AI methods can help scientists take their work to the next level, and The drug discovery process can be massively accelerated.” from Cambridge and University College London respectively.

“AI methods will be used not only to analyze data, but also to build powerful predictive and productive models of complex biological events,” he said.

Alphabet has several other companies working on health care, including Verily, which is developing software for the health care sector, and Calico, which is working on aging and extending human life.

DeepMind has also worked on health care, and used to have its own dedicated DeepMind health division. However, it was absorbed by Google in 2018 after a controversial deal with Britain’s National Health Service.

Since then, DeepMind has carried out research in other areas of the life sciences and has made breakthroughs in a field called protein folding. Last year, the company announced that it had developed an AI system that could accurately predict the structure that proteins would change in just a few days, solving a 50-year-old “grand challenge.”

.

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox